A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.

Xavier Montalban,Daniel Wallace,Mark C Genovese,Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay,Amy H Kao,Hans Guehring

Neurodegenerative disease management（2023）

引用 0|浏览3

暂无评分

摘要

The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要